Three withdrawals in advanced ovarian cancer spell trouble for PARP class
When AstraZeneca and Merck’s PARP inhibitor Lynparza was approved for advanced ovarian cancer back in 2014, FDA’s current Oncology Center of Excellence director Richard Pazdur touted it as the first in a “targeted, more personalized” new class of medicines for patients who often relapse after chemotherapy.
Almost a decade later, that option is once again off the table for some patients as three pharma giants yank late-stage indications from their labels over a potential increased risk of death.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
